TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06190899: Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Sponsor: Celcuity Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,924,230

Rescue Site Savings

+$1,256,640

Unlock Full NCT06190899 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06190899 Rescue Dossier →